Cardiac troponin T as a prognostic marker in patients with heart failure : a 3-year outcome study

Mesut Demir1, Mehmet Kanadasi, Onur Akpinar

  • 1Department of Cardiology, Cukurova University, School of Medicine, Adana, Turkey. mdemir@cu.edu.tr

Angiology
|November 21, 2007
PubMed

Insights

Elevated cardiac troponin T (cTnT) in congestive heart failure (CHF) patients indicates higher mortality risk. Early identification of worsening CHF may be possible using cTnT levels.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Cardiac troponin T (cTnT) is a specific marker for myocardial cell death.
  • Elevated cTnT levels are observed in some congestive heart failure (CHF) patients.
  • The association between cTnT release and CHF decompensation requires further investigation.

Purpose of the Study:

  • To test if decompensated CHF is linked to increased cTnT release.
  • To correlate cTnT levels with patient outcomes in CHF.
  • To identify cTnT as a potential predictor of mortality and morbidity in CHF.

Main Methods:

  • Studied 55 hospitalized CHF patients (38-86 years).
  • Assessed cTnT levels, with >or=0.1 ng/mL considered positive.
  • Evaluated left ventricular ejection fraction (EF) via echocardiography.
  • Conducted 3-year annual follow-up for mortality and hospital admissions.

Main Results:

  • cTnT was positive in 20% of patients.
  • cTnT-positive patients had lower EF and higher NYHA classification.
  • Mortality rate was significantly higher in cTnT-positive patients (72.7% vs. 38.6%).
  • cTnT positivity independently predicted mortality and morbidity.

Conclusions:

  • cTnT positivity is an independent risk factor for long-term mortality and morbidity in CHF patients.
  • Elevated serum cTnT may help identify patients with worsening CHF.
  • This finding supports the use of cTnT for risk stratification in heart failure management.

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...